Marvel Biosciences signs letter of intent for Phase 1 trial of MB-204

October 6, 2026 6:45 AM

Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF) has signed a letter of intent with Novatech, a clinical contract research ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found